It should be noted that patients from Group 4 were not tested for germline mutations in BRCA1/BRCA2 because of the criteria adopted by the Oncogenetics Department of Barretos Cancer Hospital (Palmero et al., 2016b). This evidence concerns the gene BRCA2 and cancer.